Ontology highlight
ABSTRACT:
SUBMITTER: Sajjadi E
PROVIDER: S-EPMC10106673 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature

Frontiers in molecular biosciences 20230403
The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, without gene amplification) tumors is challenged by methodological and analytical variables that might influence the sensitivity and reproducibility of HER2 testing. To open all possible therapeutic opport ...[more]